Original ArticleEndomyocardial biopsy in differential diagnosis between arrhythmogenic right ventricular cardiomyopathy and dilated cardiomyopathy: an in vitro simulated study
Introduction
The clinical characterizations of arrhythmogenic right ventricular cardiomyopathy (ARVC) are frequent ventricular tachycardia, heart failure, and high risk of sudden cardiac death (SCD) [1], [2]. Although the morbidity incidence of ARVC is estimated at 1:1000 to 5000 [2], more than 20% of SCDs are considered to be caused by ARVC [3], [4]. The pathological characterization of ARVC is progressive fibrofatty replacement of ventricular myocardium [1], [2], [5], [6], [7], and the fibrofatty replacement occurs primarily in the right ventricular (RV) anteroapical region and at the RV midoutflow tract (RVOT) and inferior subtricuspid. These three regions are called the “triangle of dysplasia” [7], [8]. Other regions, including the left ventricle (LV), can also be involved [2], [9].
The clinical characterizations of dilated cardiomyopathy (DCM) are contractile progressive dysfunction of the LV often with arrhythmias but less prominent [10].
The Taskforce Criteria 2010 (TFC-2010) are the latest criteria proposed to diagnose ARVC, composed of six categories. In each category, it has major and minor criteria. Tissue characterization of endomyocardial biopsy (EMB) sections is one of the six categories in TFC-2010, and the major criterion of this category is residual myocytes less than 60% by morphometric analysis (or <50% if estimated), with fibrous replacement of the RV free wall in one or more samples in EMB sections [11]. This major criterion in TFC-2010 comes from an article in the European Heart Journal by Basso et al. [12]. As mentioned by Basso et al., EMB has the highest specificity among testing for ARVC, so EMB is the most important test for diagnosing ARVC, but there is no comparison of tissue components in transmural sections between ARVC and DCM to demonstrate that the diagnostic efficacy of EMB is not a false-positive finding caused by a limited sampling range.
Although some authors reported that EMB sampling at the RV free wall has low perforation risk in patients at an early stage whose pathological change is not advanced and not severe [13], data about EMB perforation risk are still lacking on end-stage ARVC hearts.
Although ARVC and DCM are seemingly two dramatically different entities, they have overlapping phenotypes. As is shown in some articles [2], [9], involvement of the LV was discovered in 76% of the ARVC hearts studied postmortem. On the other hand, RV could also be involved in end-stage DCM. Therefore, it is easy to misdiagnose between ARVC and DCM, and there is a need to establish a new differential diagnostic parameter for ARVC and DCM. As was mentioned above, EMB is the most important test for ARVC diagnosis. Therefore, we investigated the utility of EMB in differential diagnosis between ARVC and DCM and sought to determine the best EMB sampling site for the differential diagnosis.
Section snippets
Patients
All 35 ARVC patients who had a heart transplantation (HTx) fulfilled the ARVC TFC-2010 (without a tissue characterization of the wall category) and the current pathological criteria in ARVC transmural sections [8]. All 35 DCM HTx patients fulfilled the DCM inclusion and exclusion criteria [14]: left ventricular end-diastolic diameter (LVEDD) greater than 27 mm/m2 and left ventricular ejection fraction (LVEF) less than 45%, and no significant coronary heart disease or congenital heart disease.
Diagnostic details of ARVC participants
All 35 ARVCs were diagnosed by TFC-2010 (without tissue characterization of wall category) (Table S1). Thirty-two of the 35 ARVC participants were definitely diagnosed; 1 of the 35 fulfilled the borderline criteria, and 2 of the 35 met criteria for possible diagnosis.
Baseline and clinical data
The 35 matched DCMs were from 186 DCM HTx patients (Fig. S3). Baseline data were not significantly different between groups (Table S2). Comparison of clinical data between ARVC and DCM showed that RV diameter and LVEF in the ARVC
Discussion
The baseline parameters were balanced between the ARVC and DCM, and comparison of clinical and gross pathological data between ARVC and DCM demonstrated that these data are consistent with the theoretical phenotype of ARVC and DCM.
Conclusion
ARVC and DCM can be differentiated in transmural sections, so the good EMB differential diagnostic efficacy between ARVC and DCM is a meaningful fact regardless of the limited sampling range. EMB perforation risk at the RV free wall with end-stage ARVC cannot be neglected. The best EMB sampling site is ARV. Among participants with low perforation risk, ARV is still recommended as an EMB sampling site with good differential diagnostic efficacy between ARVC and DCM.
Clinical significance
We propose a path of differential diagnosis between ARVC and DCM using EMB among patients with low perforation risk. First, select patients whose RV wall thickness is sufficient for EMB beforehand by cardiac enhancement CT, and RV wall thickness more than 1.7 mm is considered thick enough for EMB. Then EMB is performed in these patients, and the remainder can be diagnosed as ARVC by paper-like RV wall and transmural fat replacement in the CT image.
The following are the supplementary data
Funding statements
The current study was sponsored by the CAMS Innovation Fund for Medical Sciences (2016-I2M-1-015) and the National Natural Science Foundation of China (grant no. 81670376) and was also supported by the PUMC Youth Fund and the Fundamental Research Funds for the Central Universities.
Conflict of interest
None.
References (24)
- et al.
Sudden cardiac death in children and adolescents between 1 and 19 years of age
Heart Rhythm
(2014) - et al.
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study
J Am Coll Cardiol
(1997) - et al.
Dilated cardiomyopathy
Lancet
(2010) - et al.
Safety of endomyocardial biopsy in patients with arrhythmogenic right ventricular cardiomyopathy: a study analyzing 161 diagnostic procedures
JACC Cardiovasc Interv
(2011) - et al.
Diagnosis of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy: the role of endomyocardial biopsy guided by electroanatomic voltage map
J Am Coll Cardiol
(2009) - et al.
High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy differential diagnosis by electroanatomic mapping-guided endomyocardial biopsy
J Am Coll Cardiol
(2009) - et al.
Diagnostic accuracy of right ventriculography in arrhythmogenic right ventricular cardiomyopathy
Am J Cardiol
(1990) - et al.
Arrhythmogenic right ventricular cardiomyopathy
N Engl J Med
(2017) - et al.
Arrhythmogenic cardiomyopathy
Circ Res
(2017) - et al.
Arrhythmogenic right ventricular dysplasia: a United States experience
Circulation
(2005)
Right ventricular cardiomyopathy and sudden death in young people
N Engl J Med
Pathophysiology of arrhythmogenic cardiomyopathy
Nat Rev Cardiol
Cited by (3)
Cardiomyopathies in China: A 2018–2019 state-of-the-art review
2020, Chronic Diseases and Translational MedicineCitation Excerpt :Many types of cardiomyopathies can generate arrhythmia, including not only ACM but also other conditions such as Brugada syndrome, DCM, Chagas disease, cardiac sarcoidosis, and myocarditis. Differential diagnosis can also be difficult.106 Further, early detection of ACM before SCD has always been challenging.
Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy
2022, Journal of Veterinary Internal MedicineA comprehensive strategy for managing arrhythmogenic right ventricular cardiomyopathy
2020, Turk Kardiyoloji Dernegi Arsivi